Literature DB >> 16463030

Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey.

Nadir Ghanem1, Christian Lohrmann, Monika Engelhardt, Gregor Pache, Markus Uhl, Ulrich Saueressig, Elmar Kotter, Mathias Langer.   

Abstract

To compare the diagnostic value of whole-body MRI versus radiological skeletal survey (RSS) in staging patients with plasma cell neoplasms (PCN) and to evaluate the possible therapeutic impact of the replacement of RSS by whole-body MRI. Fifty-four patients with PCN [multiple myeloma (MM), n=47; monoclonal gammopathy of unknown significance (MGUS), n=7] were studied by whole-body MRI and RSS in a monocenter prospective analysis from August 2002 to May 2004. The MRIs were performed using a rolling table platform "AngioSURF" for unlimited field of view with a 1.5-T system (Magnetom Sonata/Maestro Class, Siemens Medical Solutions, Erlangen, Germany). A coronal STIR sequence (TR5500-4230/TE102-94/TI160) was used for imaging of the different body regions, including the head, neck, thorax, abdomen, pelvis and upper and lower extremities. The RSS consisted of eight different projections of the axial and appendicular skeleton. In 41/54 (74%) patients, the results of the whole-body MRI and RSS were concordant. In 11/54 (20%) patients, both imaging techniques were negative. Bone involvement was observed in 30/54 (55%) patients; however, whole-body MRI revealed this more extensively than the RSS in 27/30 (90%) patients with concordant positive imaging findings. In 3/30 (10%) patients, both imaging techniques demonstrated a similar extent of bone marrow infiltration. In 10/54 (19%) patients, the whole-body MRI was superior to RSS in detecting bone marrow infiltration, whereas the RSS was negative. In 3/54 (6%) patients, the RSS was proven to be false positive by the clinical course, whereas the whole-body MRI was truly negative. Whole-body MRI is a fast and highly effective method for staging PCN patients by the use of a rolling table platform. Moreover, it is more sensitive and specific than RSS and reveals bone marrow infiltration and extensive disease more reliably. Therefore, whole-body MRI should be performed as an additional method of exactly staging PCN patients and - with more data in the field - may even prove to be an alternate and more sensitive staging procedure than RSS in PCN patients.

Entities:  

Mesh:

Year:  2006        PMID: 16463030     DOI: 10.1007/s00330-005-0055-7

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  29 in total

1.  Detection of bone marrow and extramedullary involvement in patients with non-Hodgkin's lymphoma by whole-body MRI: comparison with bone and 67Ga scintigraphies.

Authors:  Masami Iizuka-Mikami; Kiyohisa Nagai; Koji Yoshida; Takashi Sugihara; Yoshimasa Suetsugu; Makoto Mikami; Tsutomu Tamada; Shigeki Imai; Yasumasa Kajihara; Masao Fukunaga
Journal:  Eur Radiol       Date:  2004-02-18       Impact factor: 5.315

Review 2.  Classification and detection of bone marrow lesions with magnetic resonance imaging.

Authors:  B C Vande Berg; J Malghem; F E Lecouvet; B Maldague
Journal:  Skeletal Radiol       Date:  1998-10       Impact factor: 2.199

3.  Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates.

Authors:  A Stäbler; A Baur; R Bartl; R Munker; R Lamerz; M F Reiser
Journal:  AJR Am J Roentgenol       Date:  1996-10       Impact factor: 3.959

Review 4.  Magnetic resonance imaging of the bone marrow in hematologic malignancies.

Authors:  L A Moulopoulos; M A Dimopoulos
Journal:  Blood       Date:  1997-09-15       Impact factor: 22.113

5.  Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET.

Authors:  H E Daldrup-Link; C Franzius; T M Link; D Laukamp; J Sciuk; H Jürgens; O Schober; E J Rummeny
Journal:  AJR Am J Roentgenol       Date:  2001-07       Impact factor: 3.959

Review 6.  Management of multiple myeloma.

Authors:  R Alexanian; M A Dimopoulos
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

7.  Nonmyelomatous monoclonal gammopathy: correlation of bone marrow MR images with laboratory findings and spontaneous clinical outcome.

Authors:  B C Vande Berg; L Michaux; F E Lecouvet; M Labaisse; J Malghem; J Jamart; B E Maldague; A Ferrant; J L Michaux
Journal:  Radiology       Date:  1997-01       Impact factor: 11.105

8.  Magnetic resonance imaging of the lower vertebral column in patients with multiple myeloma.

Authors:  F X Fruehwald; D Tscholakoff; B Schwaighofer; L Wicke; A Neuhold; H Ludwig; P C Hajek
Journal:  Invest Radiol       Date:  1988-03       Impact factor: 6.016

9.  Whole-body MRI using a rolling table platform for the detection of bone metastases.

Authors:  Thomas C Lauenstein; Lutz S Freudenberg; Susanne C Goehde; Stefan G Ruehm; Mathias Goyen; Silke Bosk; Jörg F Debatin; Jörg Barkhausen
Journal:  Eur Radiol       Date:  2002-03-08       Impact factor: 5.315

10.  MRI in the detection of malignant infiltration of bone marrow.

Authors:  R H Daffner; A R Lupetin; N Dash; Z L Deeb; R J Sefczek; R L Schapiro
Journal:  AJR Am J Roentgenol       Date:  1986-02       Impact factor: 3.959

View more
  33 in total

1.  Early treatment response evaluation in patients with diffuse large B-cell lymphoma--a pilot study comparing volumetric MRI and PET/CT.

Authors:  Xingchen Wu; Prasun Dastidar; Hannu Pertovaara; Pasi Korkola; Ritva Järvenpää; Maija Rossi; Tiit Kööbi; Hannu Eskola; Pirkko-Liisa Kellokumpu-Lehtinen
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

Review 2.  The uses and limitations of whole-body magnetic resonance imaging.

Authors:  Gerwin Schmidt; Dietmar Dinter; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Dtsch Arztebl Int       Date:  2010-06-04       Impact factor: 5.594

Review 3.  The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.

Authors:  Jo Caers; Nadia Withofs; Jens Hillengass; Paolo Simoni; Elena Zamagni; Roland Hustinx; Yves Beguin
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 4.  Magnetic resonance imaging of bone marrow in oncology, Part 2.

Authors:  Sinchun Hwang; David M Panicek
Journal:  Skeletal Radiol       Date:  2007-05-11       Impact factor: 2.199

5.  Image quality improvement of composed whole-spine MR images by applying a modified homomorphic filter--first results in cases of multiple myeloma.

Authors:  M P Lichy; C Mueller-Horvat; V Jellus; W Horger; M Horger; C Pfannenberg; B Kiefer; C D Claussen; H P Schlemmer
Journal:  Eur Radiol       Date:  2008-05-29       Impact factor: 5.315

6.  Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma.

Authors:  Patric Kröpil; Roland Fenk; Lars B Fritz; Dirk Blondin; Guido Kobbe; Ulrich Mödder; Mathias Cohnen
Journal:  Eur Radiol       Date:  2007-10-09       Impact factor: 5.315

7.  (11)C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment.

Authors:  Chieh Lin; Chi-Lai Ho; Shu-Hang Ng; Po-Nan Wang; Yenlin Huang; Yu-Chun Lin; Tzung-Chih Tang; Shu-Fan Tsai; Alain Rahmouni; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-16       Impact factor: 9.236

Review 8.  Multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2010-02-11       Impact factor: 3.909

Review 9.  Whole body MRI and PET/CT in haematological malignancies.

Authors:  Chieh Lin; Alain Luciani; Emmanuel Itti; Corinne Haioun; Alain Rahmouni
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

Review 10.  Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma.

Authors:  Susanne Lütje; Jacky W J de Rooy; Sandra Croockewit; Emmeline Koedam; Wim J G Oyen; Reinier A Raymakers
Journal:  Ann Hematol       Date:  2009-12       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.